ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The therapeutic success achieved with the use of the mutant BCR-ABL kinase inhibitor mentioned in the introduction in patients with CML prompts research on inhibitors of other kinases involved in tumorigenesis.